Price to Book Value Chart

Historical Price to Book Value Data

View and export this data back to 2007. Start Trial.
Date Value
October 30, 2026 0.0445
October 29, 2026 0.0445
October 28, 2026 0.0445
October 27, 2026 0.0445
October 26, 2026 0.0445
October 23, 2026 0.0445
October 22, 2026 0.0445
October 21, 2026 0.0445
October 20, 2026 0.0445
October 19, 2026 0.0445
October 16, 2026 0.0445
October 15, 2026 0.0445
October 14, 2026 0.0445
October 13, 2026 0.0445
October 12, 2026 0.0445
October 09, 2026 0.0445
October 08, 2026 0.0445
October 07, 2026 0.0445
October 06, 2026 0.0445
October 05, 2026 0.0445
October 02, 2026 0.0445
October 01, 2026 0.0445
September 30, 2026 0.0445
September 29, 2026 0.0445
September 28, 2026 0.0445
Date Value
September 25, 2026 0.0445
September 24, 2026 0.0445
September 23, 2026 0.0445
September 22, 2026 0.0445
September 21, 2026 0.0445
September 18, 2026 0.0445
September 17, 2026 0.0445
September 16, 2026 0.0445
September 15, 2026 0.0445
September 14, 2026 0.0445
September 11, 2026 0.0445
September 10, 2026 0.0445
September 09, 2026 0.0445
September 08, 2026 0.0445
September 04, 2026 0.0445
September 03, 2026 0.0445
September 02, 2026 0.0445
September 01, 2026 0.0445
August 31, 2026 0.0445
August 28, 2026 0.0445
August 27, 2026 0.0445
August 26, 2026 0.0445
August 25, 2026 0.0445
August 24, 2026 0.0445
August 21, 2026 0.0445

Price to Book Ratio Definition

Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.

Read full definition.

Price to Book Value Range, Past 5 Years

View Price to Book Value Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Price to Book Value Benchmarks

View Price to Book Value Benchmarks
Start Trial
DBV Technologies SA 4.013
Cellectis SA 2.648
Genfit SA --
Innate Pharma SA --
Inventiva SA 2.059

Price to Book Value Related Metrics

PE Ratio 3.75
PS Ratio 1.100
Price 0.30
Earnings Yield 26.67%
Market Cap 26.44M
Operating PE Ratio 2.543